242.56

0.16% -0.39

Quest Diagnostics Inc (DGX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$242.95

Aprire:

$241.96

Volume 24 ore:

919.02K

Relative Volume:

0.86

Capitalizzazione di mercato:

$26.77B

Reddito:

$11.28B

Utile/perdita netta:

$1.07B

Rapporto P/E:

26.76

EPS:

9.0657

Flusso di cassa netto:

$1.33B

1 W Prestazione:

+1.52%

1M Prestazione:

+2.08%

6M Prestazione:

+24.36%

1 anno Prestazione:

+36.06%

Intervallo 1D:

$0.00

Intervallo di 1 settimana:

$226.22

$246.00

Portata 52W:

$171.18

$248.84

Quest Diagnostics Inc Stock (DGX) Company Profile

Nome

Quest Diagnostics Inc

Settore

Healthcare (1053)

Industria

Diagnostics & Research (44)

Telefono

(973) 520-2700

Indirizzo

500 PLAZA DRIVE, SECAUCUS

Dipendente

57,000

Cinguettio

@QuestDX

Prossima data di guadagno

null

Ultimi documenti SEC

DGX's Discussions on Twitter

Compare DGX vs TMO, DHR, NTRA, A, WAT

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
DGX Quest Diagnostics Inc	242.56	26.77B	11.28B	1.07B	1.33B	9.0657
TMO Thermo Fisher Scientific Inc	693.02	256.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.00	163.09B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	410.82	59.22B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	177.49	50.04B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	468.55	46.03B	3.77B	449.25M	240.68M	7.8556

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-30	Aggiornamento	Barclays	Equal Weight → Overweight
2025-08-25	Downgrade	Robert W. Baird	Outperform → Neutral
2025-04-02	Iniziato	Redburn Atlantic	Buy
2025-03-04	Downgrade	Citigroup	Buy → Neutral
2025-01-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-12-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Ripresa	Jefferies	Buy
2024-10-23	Aggiornamento	Robert W. Baird	Neutral → Outperform
2024-08-28	Ripresa	Evercore ISI	In-line
2024-07-10	Aggiornamento	Citigroup	Neutral → Buy
2024-02-26	Iniziato	Leerink Partners	Market Perform
2024-02-07	Aggiornamento	Jefferies	Hold → Buy
2024-01-03	Iniziato	Barclays	Equal Weight
2023-12-12	Aggiornamento	BofA Securities	Neutral → Buy
2023-06-29	Iniziato	Piper Sandler	Neutral
2023-05-02	Downgrade	BofA Securities	Buy → Neutral
2023-04-03	Aggiornamento	Citigroup	Sell → Neutral
2023-01-23	Iniziato	Evercore ISI	In-line
2022-11-17	Downgrade	Citigroup	Neutral → Sell
2022-08-22	Ripresa	Morgan Stanley	Equal-Weight
2022-04-04	Downgrade	Citigroup	Buy → Neutral
2022-02-23	Downgrade	UBS	Buy → Neutral
2022-02-02	Downgrade	Jefferies	Buy → Hold
2022-01-28	Downgrade	Deutsche Bank	Buy → Hold
2021-05-04	Aggiornamento	UBS	Neutral → Buy
2021-03-12	Downgrade	Robert W. Baird	Outperform → Neutral
2020-10-21	Aggiornamento	Argus	Hold → Buy
2020-07-29	Aggiornamento	KeyBanc Capital Markets	Sector Weight → Overweight
2020-07-14	Aggiornamento	BofA Securities	Neutral → Buy
2020-06-09	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2020-06-02	Aggiornamento	Deutsche Bank	Hold → Buy
2020-04-28	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-04-27	Aggiornamento	Citigroup	Neutral → Buy
2020-04-27	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2020-03-27	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-01-08	Iniziato	Wells Fargo	Underweight
2020-01-07	Downgrade	Barclays	Overweight → Equal Weight
2019-12-19	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-07-15	Downgrade	Goldman	Neutral → Sell
2019-04-02	Aggiornamento	Jefferies	Hold → Buy
2019-03-18	Ripresa	Credit Suisse	Neutral
2019-01-31	Downgrade	Argus	Buy → Hold
2019-01-17	Iniziato	UBS	Neutral
2019-01-03	Downgrade	BofA/Merrill	Neutral → Underperform
2018-12-03	Downgrade	BofA/Merrill	Buy → Neutral
2018-11-30	Downgrade	Goldman	Buy → Neutral

Mostra tutto

Quest Diagnostics Inc Borsa (DGX) Ultime notizie

Oct 27, 2026

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's - Seeking Alpha

Oct 26, 2026

Form 144 QUEST DIAGNOSTICS INC For: 26 October By Investing.com - Investing.com Canada

Oct 26, 2026

Form 144 QUEST DIAGNOSTICS INC For: 26 October By Investing.com - Investing.com UK

Oct 26, 2026

A director proposes selling 1,203 shares of Quest Diagnostics (NYSE: DGX). - Stock Titan

Oct 26, 2026

Oct 23, 2026

Quest Diagnostics Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Unauthorized Access to Patient Records - Morningstar

Oct 23, 2026

Quest Diagnostics 3Q 2026: Revenue $3.1B, Net income $312M, EPS $2.78— 10-Q Summary - TradingView

Oct 23, 2026

Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach - TechCrunch

Oct 23, 2026

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Oct 23, 2026

Quest Diagnostics reports unauthorized access to lab system, says patient information may have been compromised - WRNJ Radio

Oct 23, 2026

Quest Diagnostics Data Breach Exposed ‘Certain Patient Records’ - SecurityWeek

Oct 23, 2026

Oct 22, 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $254.5, Implies 7% Upside - TradingView

Oct 22, 2026

Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance

Oct 22, 2026

Quest Diagnostics confirms patient information accessed in cyberattack, systems temporarily shut down - Fox Business

Oct 22, 2026